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Introduction
Respiratory syncytial virus (RSV) is the most common viral 
cause of severe lower respiratory tract infection (LRTI) among 
infants and children under 5 years old worldwide, with the greatest 
burden occurring in developing countries1. Most children experi-
ence an RSV infection episode by the age of two years, with peak 
rates of infection occurring in the first year of life2. Re-infections 
occur throughout life3 as RSV infections provide incomplete or 
waning immunity. There are no licensed RSV vaccines but there 
is heightened activity in vaccine development4–8.
Vaccine delivery strategies should be informed by detailed under-
standing of RSV transmission dynamics. To reduce the circulation 
of RSV, identifying which groups are responsible for majority of 
the infections is critical. Transmission potential can be estimated by 
a combination of mixing patterns9 and virus shedding (viral density 
and duration). Human experimental infection with RSV reported 
that volunteers inoculated with a higher dose of virus (4.7 log10 
tissue culture infectious dose (TCID)50 of RSV A2) were more 
likely to be infected than those given low doses of the inoculum 
(3.7 log10 TCID50 of RSV A2)10, suggesting that individuals who 
shed more virus are likely to be more infectious. Determining 
quantities shed and the related underlying factors, will help in 
predicting the spread of infection in a population and identify key 
groups to target for infection control. Previous studies have used 
the duration of shedding to identify individuals with the great-
est potential for infection spread11, based on the assumption that 
they have a higher number of infectious contacts. Several studies 
report on the duration of RSV shedding with mean values ranging 
from 4.5 to 11.2 days12,13. In addition to variation in assay type, 
determinants included history of RSV infection12, age, infection 
severity, detection of other viruses before and during the RSV 
infection, and presence of concurrent RSV infections in the same 
household13. These studies and others14,15 do not account for the 
temporal changes in quantity of virus shed. Experimental RSV 
infection studies indicate that an individual infection episode 
begins with low viral shedding, which rises with time as the virus 
continues to replicate within epithelial cells and finally declines as 
the infection clears16.
The current analysis aims to include temporal changes in viral 
excretion in estimating the total amount of virus shed during an 
individual RSV infection episode. Relative to the duration of 
shedding, this may provide an improved correlate of infectiousness 
and help in identifying the key factors influencing RSV shedding 
patterns. Such data are informative in formulating vaccine product 
profiles and designing prevention strategies for RSV.
Methods
Data
The RSV infection data arise from an intensively followed cohort 
of 47 households with 493 occupants in rural coastal Kenya. 
The details of the study have been described elsewhere13,17,18. In 
summary, throughout an RSV season spanning 26 weeks 
(December 2009–June 2010), nasopharyngeal swabs (NPS) were 
collected by trained field assistants every 3–4 days, irrespective 
of symptoms, from 47 RSV naïve infants and their household 
members. Households were selected through the Kilifi Health and 
Demographic Surveillance System (KHDSS) and local community 
health workers and were considered eligible if they had a child born 
after 1st April 2009. The infants were assumed to be RSV naïve 
because they were born after the 2008/2009 RSV season. A total 
of 16928 NPS collections were tested for RSV (groups A and B) 
and other prevalent respiratory viruses (adenoviruses, rhinovi-
ruses and human coronaviruses (NL63, 229E and OC43)) using 
multiplex real time polymerase chain reaction (PCR) assay as pre-
viously described19. As PCR cycles proceed the quantity of product 
detected rises and at some point passes through a user assigned 
threshold for detection (set at the point of observable exponential rise 
in product), known as the cycle threshold (Ct). The earlier (lower) 
the Ct value the higher the starting concentration of target sequence 
(equated with viral density). As a cut-off, samples with Ct values 
of 35.0 and below were considered positive. An RSV infection 
episode was defined as the period within which an individual pro-
vided specimens which were PCR positive for the same infecting 
RSV group with no more than 14 days separating any two positive 
samples. A household outbreak was defined as a period in which a 
household experienced more than one individual infection episode, 
without there being more than 14 days between any two infection 
episodes. A primary/index case was a person first identified to have 
an RSV infection leading to a household outbreak. A first episode 
was the first episode in that season that an individual had while 
a subsequent episode was a second or third episode that a person 
may have had during the follow up. Virus test results, recorded in 
Ct values, were converted to log10 ribonucleic acid (RNA) copy 
numbers (direct measure of viral density) to enable plotting of 
the time – concentration curve. The equation y = -3.308x + 42.9 
was used to convert Ct values (y), to their log10 RNA equivalents 
(x), as a way of quantifying RNA20. The converted values are 
hereafter referred to as viral densities. Amount of virus shed during 
an infection episode was estimated by calculating the area under 
the time-concentration curve (AUC) using the trapezoidal rule21. 
The peak viral density for each episode was identified as the 
highest measured viral density in an infection episode.
Calculation of area under curve
For every episode, calculation of the area under the curve involved 
plotting a time concentration (viral density) curve of the differ-
ent viral densities over the duration of shedding of the episode 
(Figure 1). Three scenarios were explored which take account 
of uncertainty arising from the sampling intervals, estimating a 
minimum, midpoint and maximum AUC, for which calculations 
are described below, aided by illustrations in Figure 1A – C). For 
each scenario, two examples are described: the first with one posi-
tive observation, and the second with three positive observations 
(Figure 1). This analogy can be extended to episodes with a 
different number of positive observations. The number of positive 
observations in an episode ranged from 1 to 11.
a) Minimum area under curve. The minimum AUC estimate 
assumed that an individual started shedding on the day of the first 
positive sample in an infection episode, and stopped shedding on the 
day of the last positive sample of the episode, in the form shown in 
Figure 1A, with viral density Y1, and hence calculated as,
AUC = 0.5 * Y1 * 1 day.
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If an episode had two or more consecutive positive observations, 
AUC was calculated by including all days in which they were 
assumed to be shedding. Thus, for an example episode with three 
positive observations, with viral density Yi, i=1,3, respectively, 
then:
AUC = (0.5 *((D2– D1) +1) * (Y1+ Y2)) + (0.5 * (D3– D2) * 
(Y2+ Y3))…………….….. (i).
Note the addition of one day to the calculation such that shedding 
on day 1 is included. Days with zero Ct values in between samples 
with positive viral densities were taken to have zero viral density. 
Therefore, AUC was calculated as in (i) above including both zero 
and non-zero observations. For left and right censored episodes, 
calculation of the amount of virus remained as in (i) above.
b) Midpoint area under curve. The midpoint AUC estimate assumed 
that an individual began shedding midway between the day of the 
first positive sample of an infection episode and the day of the last 
negative sample before the start of the episode. An individual was 
assumed to have stopped shedding midway between the day of the 
last positive sample of an episode and the day of the first negative 
sample after the episode (Figure 1B). 
Hence to calculate the AUC for an episode with one positive 
observation:
Let the midpoint days be: x = (DA + D1)/2, and y = (DB + D1)/2, 
where DA, DB and D1 are, respectively, the day of the last negative 
sample before the start of the episode; day of the first negative sam-
ple after the end of the episode; day of the first positive sample, 
hence
AUC = 0.5 *((y - x) + 1) * Y1. 
To calculate the AUC for an episode with three positive 
observations:
Let the midpoint days be: x = (DA + D1)/2, and y = (DB + D3)/2, 
where D2 and D3 are the days of the second and third positive 
samples, respectively, so
Figure 1. Schema depicting the patterns of virus shedding for three possible scenarios, A, B and C, graphically representing the minimum, 
midpoint and maximum AUC calculations, respectively, defined in the Methods text. For each scenario two example episodes are shown, the 
first with only one virus positive sample, and the second with three virus positive samples. Yi - Viral density values; DA – Day of last negative 
sample before start of episode; DB – Day of first negative sample after end of episode; D1 – Day of first positive sample; D2 – Day of second 
positive sample; D3 – Day of third positive sample.
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AUC = (0.5 * Y1 * ((D1- x) +1)) + (0.5 * (D2 – D1) * (Y1 + Y2)) + 
(0.5 * (D3– D2) * (Y2 + Y3)) + (0.5 * Y3 * (y - D3)).....................(ii).
Days with zero Ct values in between samples with positive 
viral densities were taken to have a Ct value of 40, and the AUC 
calculated as in (ii) above.
For left and right censored episodes, with unknown DA and DB, 
respectively, shedding was assumed to start 1.85 days (ie half the 
mean sampling interval) before the first observed day of shed-
ding, D1, and to finish 1.85 days after the last positive (D3 in the 
example of (ii) above). Hence, in (ii) above, (D1-x) and (y-D3) were 
replaced with the value 1.85 days, for left and right censored data, 
respectively.
Maximum area under curve. To calculate the maximum AUC, 
individuals were assumed to have begun shedding immediately 
after the last negative sample before the start of an episode, and 
stopped shedding immediately before the first negative sample 
after the episode (Figure 1C). The viral densities for the days when 
individuals were considered to have begun and stopped shedding 
were assumed to be zero. Zero Ct values in between samples with 
positive viral densities were substituted with the average of the two 
immediate positive values.
Hence, to calculate the AUC for an episode with one positive 
observation:
AUC = 0.5 *(DB - DA) * Y1,
and to calculate the AUC for an episode with three positive 
observations:
AUC = (0.5 * Y1 * (D1- DA)) + (0.5 * (D2– D1) * (Y1+ Y2)) + 
(0.5 * (D3– D2) * (Y2 + Y3)) + (0.5 * Y3 * (DB - D3)) .........……(iii).
Left and right censored episodes were treated similarly to that for 
midpoint AUC, but assuming shedding began and ended 3.7 days 
(i.e. the mean sampling interval) before the first positive sample of 
an episode and after the last positive sample of an episode. Hence 
in (iii) above, (D1-DA) and (DB-D3) were replaced with the value 3.7 
days, for left and right censored data, respectively.
Statistical analysis
Data were analysed using Stata version 13.1 (StataCorp. College 
Station, TX: StataCorp LP. RRID:SCR_012763) and RStudio 
version 0.99.489 (RStudio Team. RStudio, Inc., Boston, MA. RRID:
SCR_000432). The differences in the distribution of amount of 
virus by various characteristics was tested using the Wilcoxon rank-
sum test and Kruskal Wallis rank test as appropriate. Spearman’s 
rank correlation coefficient was used to find the association between 
the different measures of viral quantity calculated. Linear regression 
was used to identify the main factors associated with the amount 
of virus shed, i.e. AUC. Possible covariates were chosen from the 
dataset by selecting those that could plausibly be associated with 
AUC. A univariable analysis was carried out to identify factors 
independently associated with AUC. All variables with a p-value of 
<0.1 in the univariable analysis were included in the multivariable 
regression analysis. The final multivariable regression model was 
developed by a backward stepwise procedure, rejecting variables 
with a p-value >0.05 in likelihood ratio tests. Risk factors were 
removed in descending order of strength of association determined 
from the multivariable analysis. Two interactions were tested in 
the multivariable model. An interaction between age and symptom 
status was tested to determine if the effect of age on the amount 
of virus shed varied by symptom status. An interaction between 
age and primary/secondary case status was also tested because it 
was suspected that the effect of age on the amount of virus shed 
could vary by primary/secondary case status. The final model was 
adjusted for sex, even though it was not statistically significant.
Ethics
The household study was approved by the KEMRI Ethical Review 
Committee in Kenya, SSC No. 1651, and the Biomedical Research 
Ethics Committee at the University of Warwick in the United 
Kingdom. Data was anonymised by using identification IDs for 
each participant and household.
Consent
Written informed consent was obtained from all participants and/or 
their parents or guardians.
Results
Infection episodes
The mean (SD) sampling interval was 3.7 (2.3) days. The median 
number of swabs collected for an individual was 41, with the 
minimum being 1 swab and the maximum 48 swabs. There were 
537 (3.2%) samples from 179 individuals that were positive 
for RSV. RSV group A only, group B only, and group A/B 
co-infections were detected in 231 (1.5%), 287 (1.8%), and 19 (0.1%) 
NPS collections, respectively (Table 1). From the 179 infected 
individuals, a total of 208 infection episodes were observed dur-
ing the six-month study period; 180 were fully observed episodes 
while 13 and 17 were left and right censored episodes respec-
tively. Two episodes were both left and right censored. Eighty 
three (39.9%), 111 (53.4%), and 14 (6.7%) episodes were associ-
ated with RSV group A, group B and a co-infection respectively. 
One hundred and fifty two (84.9%) individuals had one epi-
sode, while 25 (14.0%) and 2 (1.1%) had two and three episodes 
respectively (Table 1). In addition, 24 (60.0%) households had one 
outbreak, while 5 (12.5%) had two outbreaks.
Overall amount of RSV shed
The median (interquartile range) of the amount of virus shed 
estimated by the minimum, midpoint and maximum AUC 
approaches was 31.1 (15.4, 57.9), 41.7 (24.3, 68.0), and 50.7 (31.0, 
79.6) log10 RNA copies per infection episode, respectively. The 
minimum and maximum AUC estimates were strongly correlated 
with the midpoint AUC estimates (r=0.97 P < 0.001 and r=0.96 P 
< 0.001, respectively) (Supplementary Material Figure S1). The 
alternative measures of RSV shedding, (shedding duration and 
peak viral density), were also strongly correlated to the midpoint 
AUC estimates; 0.94 (P < 0.001) and 0.74 (P < 0.001) (Figure 2). 
Note, however, that within a narrow range of AUC the range of peak 
virus can be wide. The distribution of the amount of RSV shed by 
the various characteristics explored were similar regardless of the 
estimation method (i.e. minimum, midpoint, or maximum AUC) 
(See Supplementary Material Table S1) and hereafter only the 
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Table 1. Distribution of RSV infection episodes among 179 infected individuals 









n % n % n %
Age at infection <1y 31 17.3 35 16.8 2424.1 30.7
1-<5y 41 22.9 51 24.5 2011.8 25.5
5-<15y 64 35.8 73 35.1 2241.7 28.4
15-<40y 35 19.6 40 19.2 854 10.8
> = 40y 8 4.5 9 4.3 366.9 4.6
Sex Female 96 53.6 118 56.7 4392.4 55.6
Male 83 46.4 90 43.3 3506.2 44.4
Symptomatic No 71 39.7 90 43.3 2145.2 27.2
Yes 108 60.3 118 56.7 5753.3 72.8
Participant in schoold No 101 56.4 119 57.2 5184.2 65.6
Yes 78 43.6 89 42.8 2714.4 34.4
Infecting RSV group RSV A 88 49.2 83 39.9 2838.1 35.9
RSV B 113 63.1 111 53.4 4170 52.8
Co-infection 14 7.8 14 6.7 890.5 11.3
Order of the episode 
in individual 
First 152 84.9 179 86.1 7130.3 90.3
Subsequent 27 15.1 29 13.9 768.3 9.7
Introducer of RSV 
infection in household 
Primary case 57 31.8 70 33.7 2372.7 30
Others 131 73.2 138 66.4 5525.9 70
Living with smoker in 
household 
No 155 86.6 181 87 7081.2 89.7
Yes 24 13.4 27 13 817.3 10.3
Household size < = 5 22 12.3 25 12 992.6 12.6
6 to 10 52 29.1 61 29.3 2605.3 33
11 to 15 35 19.6 40 19.2 1360.5 17.2
>15 70 39.1 82 39.4 2940.1 37.2
Infection with other 
viruses 
Yes 96 53.6 110 52.9 5054.6 64
No 93 46.4 98 47.1 2844 36
During Household 
outbreak 
Yes 165 92.2 192 92.3 7460.6 94.5
No 14 7.8 16 7.7 438 5.5
aNumber of infected individuals; bNumber of infection episodes; cTotal amount of virus shed 
(midpoint AUC). dIncludes some participants in the age groups 1-<5 years, 5-<15 years, and 15-<40 
years only.
midpoint estimates are reported. Viral densities by time over the 
study period did not change for RSV B, but showed a slight trend 
for decrease over time for RSV A (see Supplementary Material 
Figure S2).
Amount of RSV shed by various characteristics
The median (interquartile range) amount of virus shed was 71.0 
(IQR: 42.3, 96.7), 37.7 (IQR: 24.6, 54.4), 25.0 (IQR: 14.1, 36.7), 
14.6 (IQR: 9.4, 32.4), and 56.3 (IQR: 5.7, 65.3) log10 RNA copies 
for individuals aged <1y, 1-<5y, 5-<15y, 15-<40y and >=40y 
respectively (Figure 3a) based on the midpoint approach, and 
there was strong evidence of a difference in distribution of AUC in 
different age groups (P = 0.001). Infection episodes associated 
with symptoms had a higher median amount of virus shed than 
those without symptoms (42.5 (IQR: 25.1, 66.0) vs 19.0 (IQR: 9.8, 
29.0) log10 RNA copies; P < 0.001) (Figure 3b). Most symptomatic 
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Figure 2. Scatter plots showing the correlation between (a) duration of shedding (days) and (b) peak viral density (log10 RNA) and midpoint 
AUC estimates.
Figure 3. Box and whisker plots showing the distribution of amount of virus shed using the midpoint estimates by a) age b) symptoms c) RSV 
type d) order of episode in individual, and e) primary or secondary episode in household.
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episodes were experienced by younger individuals (<20 years), 
while older individuals above 20 years mostly had asymptomatic 
episodes (Figure 4). Episodes associated with RSV A only, RSV B 
only, and RSV group A/B co-infection had a median amount of virus 
of 26.4 (IQR: 15.1, 52.4), 28.8 (IQR: 13.2, 48.9), and 66.1 (IQR: 
42.1, 75.5) log10 RNA copies respectively (P = 0.003) (Figure 3c). 
Co-infection (associated with adenoviruses, rhinovirus, or corona-
viruses) episodes had a median amount of virus of 38.7 (IQR: 19.6, 
65.3) log10 RNA copies, while episodes not associated with any 
other infection had a median of 25.0 (IQR: 11.1, 37.0) log10 RNA 
copies, and there was strong evidence (P = 0.003) of a difference in 
the distribution of AUC in these two groups of episodes. Episodes 
that occurred during a household outbreak had a median amount 
of virus of 31.6 (IQR: 15.9, 54.8) log10 RNA copies, compared to 
a median of 20.3 (IQR: 10.2, 35.4) log10 RNA copies for episodes 
that were not associated with household outbreaks, though there 
was weak evidence of a difference in medians (see Supplementary 
Material Table S1). Infants had the highest peak viral density, and 
longest duration of shedding (Figure 5). Lowering the threshold 
below 35 Ct did not greatly change the results but reduced the total 
number of infections (see Supplementary Material Figure S3).
Factors associated with the amount of virus shed
The final regression model identified age, sex, symptom status, RSV 
infecting group, order of episode in an individual, and primary/ 
secondary infection in the household as the main factors associated 
with the amount of virus shed. The effect of age on the amount 
of virus shed seemed to vary with primary/secondary case status 
(Table 2). The results reported here are, therefore, adjusted for 
the above covariates. The difference in mean amount of virus in 
secondary case episodes for age groups 1-<5y, 5-<15y, 15-<40y, 
and >=40y when compared to infants <1y was; -41.6 (95% 
CI: -53.7, -29.6), -43.1 (-55.5, -30.7), -50.6 (95% CI: -64.9, -36.3), 
and -29.4 (95% CI: -50.8, -8.1) log10 RNA copies respectively 
(P < 0.001). There was no evidence (p=0.594) of a difference in 
amount of virus by age for primary cases. There was an increase 
in mean amount of virus for symptomatic episodes compared to 
asymptomatic episodes by 14.1 (95% CI: 6.3, 21.9) log10 RNA 
copies, and strong evidence of a difference in means (P < 0.001). 
Mean amount of virus shed for subsequent episodes of individuals 
in the study RSV season compared to first infections was -10.4 
(95% CI: -20.0, -0.8) log10 RNA copies (P = 0.03). The difference 
in mean amount of virus for episodes of RSV B only and RSV 
A/B co-infections when compared to episodes of RSV group A 
only was 3.7 (95% CI: -3.1, 10.5) log10 RNA copies, and 21.3 (95% 
CI: 7.3, 35.3) log10 RNA copies (P = 0.012) respectively (Table 2). 
For all age groups, there was no evidence of a difference in 
amount of virus for primary and secondary episodes. There was 
no evidence that the effect of age on amount of virus varied by 
symptom status.
Discussion
We report a detailed analysis of RSV shedding patterns in which the 
amount of virus shed during the course of an infection was quan-
tified, and factors associated with the quantity shed were identi-
fied. Young age at infection, presence of respiratory symptoms, 
intra-household acquisition of infection, being a first infection 
episode in the season for an individual, and having a co-infection 
were associated with increased amounts of RSV shed. The major-
ity of virus available for transmission during an RSV epidemic 
appears to arise from individuals in their first year of life and there-
fore undergoing their first RSV infection episode (since all were 
born after the preceding RSV epidemic). Household size did not 
influence the per person amount of virus shed, and neither did 
the presence of a smoker in the household. The apparent effect 
of school going status on amount of virus shed was confounded 
by age, as school was attended by young individuals, who in turn 
shed more virus. RSV viral densities appeared to be low for most 
individuals in the beginning of the season but increased well into 
the season. This was a reflection of the occurrence of the RSV 
epidemic. Viral densities for RSV B were first to increase followed 
by viral densities for RSV A. RSV B infections spread to more 
individuals probably due to earlier onset by chance compared to 
RSV A infections.
Of particular importance is the finding that 90.3% of virus shed was 
from individuals experiencing their first episode in the RSV season 
(Table 1). Modelling studies have been unable to determine to what 
extent reinfections contribute to transmission11,22, which has a big 
influence on predictions of the effect of vaccination on transmission 
dynamics11. Whilst these results do not include the opportunities 
to transmit, which will be generally higher for school-going chil-
dren undergoing their second or third infection9, they suggest that 
people with their first episode in the season are the most likely to 
transmit infection when they contact susceptible individuals. 
Peak viral density and duration of infection episodes were highly 
Figure 4. Scatter plot showing the relationship between midpoint AUC and age stratified by symptom status.
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Figure 5. Scatter plots showing the relationship between duration of shedding and peak viral density stratified by age.
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correlated with the amount of virus shed. Infants had the highest 
peak viral density, and longest duration of shedding (Figure 5).
Infants shed the highest median amount of virus followed by 
individuals aged 40 and above. The adults (15 to 39 years) shed the 
lowest amounts (Figure 3a). Acquired immunity (following exposure 
to RSV) and physiological development of the airways with age 
have been linked with reduced risk of severe RSV disease12,13. 
We speculate that elderly individuals are more prone to infection 
because of their deteriorating immune response which could explain 
the higher amount of virus in individuals over 40 years, compared 
to other adults. However, this study cannot discriminate between 
the two factors of young age and a first infection as the dominant 
factors associated with shedding (infants all had first infections, 
and we do not know the history of previous infection in all other 
ages). Individuals with a co-infection of RSV group A and B shed 
twice the amount of virus compared to those infected with either 
RSV A or B only, suggesting that the physiological infection proc-
esses for two viruses might be independent (rather than competitive 
or synergistic). Similar patterns of shedding were reported based 
on shedding duration estimates using this dataset13 and others12,15. 
These findings can provide a hint to pathogenesis of RSV disease6. 
A recent experimental study has reported disease severity to be 
closely related to viral load16 even though another shows contrasting 
observations on disease severity and viral load link10. Our study 
showed a strong positive association between virus shedding and 
presence of respiratory symptoms. Symptomatic individuals shed 
higher amounts of virus than asymptomatic individuals irrespective 
of age. Overall those who were both young (<5 years) and symp-
tomatic contributed to the highest amount of virus shed (51.8%). 
Using amount of virus as a correlate of infectiousness, these 
two factors are associated with virus spread within the community 
and in families and thus have direct implications in design and 
delivery of transmission-blocking interventions such as vaccines.
This analysis had some limitations. First, the nasal samples were 
collected with intervals of 3 to 4 days hence a complete profile of 
the viral density changes over time could not be captured. This has 
implications on the accuracy of our AUC estimates. However we 
minimize this by using a conservative approach providing three 
possible estimates i.e. minimum, midpoint and maximum estimates 
as detailed in the Supplementary Material. Furthermore, the three 
measures were strongly correlated and their variations by various 
characteristics such as age and symptoms, were comparable. 
Second, Ct values were converted to RNA copies using published 
associations20 hence providing only a relative measure of virus 
Table 2. Factors influencing amount of virus shed in rural coastal Kenya during the 
2009/2010 RSV season: Multiple linear regression analysis.




1-<5y -0.21 -18.4, 17.9 0.594
5-<15y -7.3 -23.0, 8.4
15-<40y -12.7 -30.7, 5.2




1-<5y -41.6 -53.7, -29.6 <0.001
15-<15y -43.1 -55.5, -30.7
15-<40y -50.6 -64.9, -36.3
>=40y -29.4 -50.8, -8.1
Symptomatic No Ref*
Yes 14.1 6.3, 21.9 <0.001
Order of infection 
in individual 
First Ref*
Subsequent -10.4 -20.0, -0.8 0.03
RSV group RSV A Ref* 0.012
RSV B 3.7 -3.1, 10.5
Co-infection 21.3 7.3, 35.3
Sex 
Female Ref* 0.287
Male -4.0 -10.2, 3.0
aDifference in mean AUC in comparison to reference category using midpoint estimates. * Reference 
category.
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density in the sample taken rather than absolute values of the 
amount of virus shed. Using the inverse of the Ct values as a 
measure of viral load did not change the distribution of AUC by 
various characteristics or any conclusions made from the results. 
There are no published studies using our approach in a community 
setting to facilitate comparison. Our approach takes into account 
both changing viral load and the duration of shedding making it more 
robust. However, its accuracy also relies on user selected thresholds 
for measures of viral load, and this could result in some differences 
in findings across studies. A quantitative PCR would be preferable. 
Third, there is inherent variability in estimated viral load due to 
variation (both biological and methodological) in the amount of 
virus collected using a nasopharyngeal swab. Deep NPS collections 
might have a higher density than perinasal swabs but events prior 
to sampling, e.g. sneezing, might introduce variations in sample 
quality. However this is likely to be non-systematic hence only 
conservatively affects our final conclusions. Finally, the assump-
tion is made that virus density as measured by PCR is a measure 
of infectious virus. The most likely limitation of this assumption is 
over-estimating the duration of and peak shedding of viable virus.
In conclusion, long shedders tend to shed more virus and are likely 
to be more infectious. However, it is also evident that individuals 
with similar durations of shedding may shed different amounts of 
virus. Individuals with a combination of high viral density and long 
shedding durations are likely to shed the most virus. This improves 
on existing literature that measures infectiousness using the duration 
of shedding only. The groups that are most likely to spread infection 
are individuals with a first infection episode, the symptomatic, and 
most predominantly, the young, which has implications on which 
groups to target for vaccination in RSV prevention strategies.
Data availability
The dataset used in this study, together with associated analysis 
code (.do), graphics code (.R), variable codebook (.pdf), and 
summary file (.txt) are available from Harvard Dataverse: 
doi:10.7910/DVN/MOTEJH23. The dataset has restricted access, 
retaining Personal Identifiable Information (specifically dates) 
for analysis duplication. Please request access as instructed in the 
Readme.txt file. Other files are open access.
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Failure to evaluate infectious viral particles and using non-infectious viral particle counts
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We agree that virus quantification from nasopharyngeal swab collections is imperfect and
will result in variation arising from the collection technique. This variation is likely to be
random and hence should not alter the patterns with respect to covariables, but make
observations more noisy. We hope readers understand the limitations and the fact that

















While we do not disagree with the reviewer that more accurate quantification of viral RNA
is possible, there is no disputing the negative consistent relationship between starting
quantity and cycle threshold. Inter-assay variation was assessed through repeated
positive controls which were monitored each run. There is, of course, the underlying high
degree of underlying biological variation referred to earlier which diminishes the value of
downstream precision in RNA load estimation. Hence we recognise we are using only
crude estimates, but these were the data available and they produce results which look
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The observed increase in AUC for co-infections of RSV A and B relative to single
infections is perplexing, so we thank the reviewer for the insights regarding interpretation




















We accept that a limitation of the original study was the absence of virus culture. A
caution on inferring virus infectiousness using the PCR quantities is explicit in the paper.
While further work will be required to link quantitative PCR copy numbers and
infectiousness it is worth noting in a carefully designed human challenge studies viral
load dynamics by qPCR mirror that of quantitative culture with qPCR consistently
overestimating viral load mainly in the recovery phase. This provides evidence of direct
proportional relationship between quantitative culture (a measure infectious virus) and
qPCR (measuring both infectious and non-infectious viruses) (DeVincenzo, Wilkinson et
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Co-detection of RSV A and B were in 19 NPS collections yielding to 14 different infection
episodes in 7 households. 4 out of the 7 households had more than one co-infection
episode. While acknowledging the challenges of interpreting co-infection data, the
 outgoing observations of clustering of the co-detections by individual and co-infection









The reverse argument is also possible. A higher proportion of shed cells would be
infected with RSV. Unless concurrent infections were actually in the very same cells
(rather than infecting other cells) then this sloughed material would actually have less
co-infection than the remaining intact cells.  In addition, the enhanced sloughing of the
epithelial cells would have been prominent in symptomatic infection episodes where
secretions will have ‘washed’ a larger surface area and the later is adjusted for in our
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A very good suggestion though our analyses showed no apparent relationship between




















Swabs were collected regardless of symptom status and days of collections were planned
to coincide for all members in same household unless someone was away. Therefore
swabbing in early phase of infection (when viral load was high) would have occurred by








Indeed this is an intriguing observation. We have interpreted this finding with caution
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  No competing interests were declared.Competing Interests:





















I have read this submission. I believe that I have an appropriate level of expertise to confirm that






Being symptomatic or not was defined both by individuals and by episodes. 
An episode was described as asymptomatic if the individual never had any respiratory
illness symptoms during the entire duration of the infection episode. An episode was
described as symptomatic if the individual had respiratory illness symptoms at least once
during the episode.
An individual was described as symptomatic if they had respiratory illness symptoms at
least once during the study period, and asymptomatic if they never had any respiratory
illness symptoms throughout the study period.
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illness symptoms throughout the study period.
Of the 71 individuals with asymptomatic episodes, 19 (26.8%) subsequently developed
symptoms within one week. The subsequent symptoms were not linked to any virus




Sampling was done irrespective of symptom status and the frequency of sampling was
not influenced by symptoms. Mild symptoms (mainly cough and running nose) were
observed among the symptomatic cases hence difficult to grade the disease severity – no
severe or very severe pneumonia cases. Nevertheless, there was no association between
symptom status and virus type. The patterns of spread within households and role of
asymptomatic cases has been discussed in detail in previous papers:
Munywoki PK, Koech DC, Agoti CN, et al. The source of respiratory syncytial virus
infection in infants: a household cohort study in rural Kenya. [electronic article].
2014;209(11):1685–92.
Munywoki, P. K., D. C. Koech, C. N. Agoti, A. Bett, P. A. Cane, G. F. Medley and D. J.
Nokes (2015). "Frequent Asymptomatic Respiratory Syncytial Virus Infections
During an Epidemic in a Rural Kenyan Household Cohort."  212(11):J Infect Dis
1711-1718.
Munywoki, P. K., D. C. Koech, C. N. Agoti, N. Kibirige, J. Kipkoech, P. A. Cane, G. F.
Medley and D. J. Nokes (2015). "Influence of age, severity of infection, and
co-infection on the duration of respiratory syncytial virus (RSV) shedding." 
 143(4): 804-812.Epidemiol Infect
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We have read this submission. We believe that we have an appropriate level of expertise to











We agree the sampling interval was not optimal for this type of analysis. However, it was
not logistically possible to collect deep nasopharyngeal swabs from ~500 participants at a
more intense frequency for six months. Furthermore, community acceptability of more
frequent sampling was an important issue. 
The following rationale was used to determine the twice-weekly (every 3.5 days) nasal
sampling frequency. Assuming individuals shed virus with mean duration of between 3.5
and 9 days, with a constant rate of recovery from shedding, and an onset on average half
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 sampling frequency. Assuming individuals shed virus with mean duration of between 3.5
and 9 days, with a constant rate of recovery from shedding, and an onset on average half
way between any sampling interval, then the proportion of individuals predicted to remain
shedding, and thus detectable, will range from 61%-82% (for 3.5-9 days duration) for a 3.5
day sampling interval. Given the need to detect infection in mild cases and in older






This is a retrospective analysis of household RSV infection data and we share the
referee’s concerns about limitations on the use of Ct values. A qPCR would have been the
best method to quantify viral load. However, a standardized multiplex RT-PCR protocol
was used which included positive controls monitored each run to ensure their Ct values
did not vary significantly.   
3. At the beginning of the Methods section, the authors specified that the AUC was calculated
using viral load in log scale, but later for the midpoint AUC, they used Ct-value, please clarify.
Viral load for calculation of minimum, midpoint and maximum AUC was presented in log
copies. Ct values are mentioned to explain how viral load for days in between collection
days was estimated before being converted to log  copies. The original viral load values
were in Ct values, which were then converted to log  copies and used to calculate AUC in
 all three scenarios (minimum, midpoint and maximum AUC). Please also see comments
in response to Referee Cowling.
 
4. Reference 21 and 23 are not accessible
Thank you. We have rectified the errors in the two references. Reference 21 should be:
‘Kreide, Donald; Lahr D. Trapezoid Rule and Simpson’s Rule [Internet]. 2010. Available
from: https://math.dartmouth.edu/~m3cod/klbookLectures/406unit/trap.pdf’, 
while reference 23 is the study dataset.
5. Without baseline demographics about the sampled cohort, I find some of this information hard to
interpret. Symptomatic infections would also be interesting to see by age group.
We have provided a brief summary of the baseline characteristics in the first paragraph of
the results section. However, more details could be accessed in our earlier publications
arising from this study whose references are provided. Figure 4 of this manuscript
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 Total AUC is the cumulative AUC for all infection episodes in a specified category eg age
group. The higher number of infection episodes in the 5-15 year age group is most likely
 due to the higher number of individuals in this age category , and this translated to the
higher total of the amount of virus shed by this age group. To compare the transmission
potential per person by age group, an average amount of virus shed per infection episode
 might be a better statistic rather than the total AUC . However, from the perspective of





In this rural community, indoor smoke from solid fuels (mainly firewood and charcoal)
was ubiquitous and likely to conceal any effects of smoke from cigarettes. In addition, we
only had 18 smokers out of the 493 participants. So, relatively few people lived with
smokers. Also, we cannot be sure how much contact members of a household had with a
smoker and if the smoker did smoke in the house or outside. A comment has been added






This limitation in extrapolating results on association of infection acquisition and
exposure and viral load from human challenge studies has been noted and discussed in
the main text. 
2. P3c1p3: I don’t think excretion is proper terminology for the process of virus shedding (nor is
viral density – which is used later on, p6)
Well noted. We have now used viral shedding consistently in the text.
3. P3c1p4: the number of sampled household members and the inclusion criteria should be added
here.
This has been described in a previous paper as stated in the methods section
4. P3c2p1: why were only adeno, corona and rhino targeted with the diagnostic PCR and not the
influenzas, parainfluenzas and hMPV? This is a very limited definition of co-infection.
Adeno, corona and rhino were the common respiratory viruses detected in a preliminary
screening of the samples from 5 randomly selected households and taken forward for the
screening of rest of the samples from the remaining households. We thus have limited
data to comment on the other respiratory pathogens.
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 data to comment on the other respiratory pathogens.
5. P6: Please clarify why data are presented as median (IQR) amounts of virus shed in one
paragraph but then as mean amounts (95%CI) of virus shed in the other
The AUC values were still slightly skewed even after log transformation. So, we presented
medians in the descriptive analysis because it is the best measure for a skewed variable.
However, the linear regression analysis coefficients are means not medians, so for the
linear regression results, we had to present means and 95% CI. 
6. P8c1p2: In Table 2 sex is not significant, but its mentioned here as an associated factor
We chose to adjust for sex a priori because sex has previously been considered an





This was a comparison of viral load values (not amount of virus) against time just to show
the reader a visual of how viral load varied depending on the month of the year. This was
to demonstrate that there is an increase in the number of positive viral load detections
during the RSV season. This has been mentioned in the results and discussion sections.
8. P8c2p3: why is it of particular importance that 90.3% of virus shed is from individuals
experiencing their first episode? Also, 179/208 episodes studied were first episodes
First episode in this case refers to the first infection detected over the study period, which
were 179 (86%). As stated earlier, the total AUC gives an idea of which groups contribute
most to community transmission of virus. It is, therefore, important to note that most virus
shed comes from individuals experiencing their first episode of the RSV season.
9. Table 2: the number of primary and secondary cases per age group would be informative here
. Thank you. This has been added
 No competing interests were disclosed.Competing Interests:
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The absolute values (viral RNA copy numbers) for AUC were not normally distributed and
were log transformed to stabilize the variances providing a suitable outcome variable for
use in linear regression analysis. The mean (SD) for the untransformed and
log-transformed values is 3.73x10 (1.34x10 ) and 6.07 (1.51), respectively. The choice of
outcome has been clarified in the manuscript.
We have re-analysed the data by the alternative route of summing the absolute viral load
values and then taking logs to estimate the AUC. The results are not substantially
different from the current method which is a summation of the log-transformed values to
estimate AUC. This is stated in the discussion.
2. In Figure 1 please clarify the y-axis metric and you might like to explain this choice as well. Is it 
viral density (copies), or log_10 copies?





The relationship between viral shedding and infectiousness is unknown. The relationship
between amount of virus shed and risk of infection might be linear or have a threshold
effect (e.g. minimum dose), in which case a logarithmic scale would be more appropriate.
The log-transformation allowed us to stabilize the variance of the outcome values,
suggesting that the measurement error of amount of virus might vary non-linearly. The
final conclusions (biological interpretation of determinants of amount of virus spread) is
similar to when using the arithmetic values since an increase in log values is also linked
 to an increase in absolute values albeit at exponential scale.
The relationship between various factors such as age, symptoms, etc and untransformed
7 8
10
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 The relationship between various factors such as age, symptoms, etc and untransformed
amount of virus is the same as that between those factors and the log-transformed
amount of virus. Using log-transformed values does not affect the final conclusions.
Determining the relationship between measures of virus shed and risk of transmission
requires a different analysis which we are undertaking. This is now reflected in the
 Discussion.
 No competing interests were disclosed.Competing Interests:
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